REG - Cambridge Cognition - Board appointments

Cambridge Cognition HoldingsAnnouncement

30/01/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240130:nRSd2731Ba&default-theme=true

RNS Number : 2731B  Cambridge Cognition Holdings PLC  30 January 2024

30 January 2024

Cambridge Cognition Holdings plc

("Cambridge Cognition" or the "Company")

 

Board appointments

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets
digital solutions to assess brain health, is pleased to announce the
appointment of Stuart Gall and Philip Rodgers ("Nick") as independent
non-executive Directors of the Company, both with effect from 1 February
2024.

As announced in the Trading Update this morning, the Company has seen revenue
growth of 7% in 2023 and an adjusted operating profit in the second half in a
difficult economic environment and is positioned to deliver further growth in
the future.  The appointments will strengthen the Board to support these
growth plans by adding additional commercial, investor relations and financial
expertise.  The additions to the Board take the number of non-executive
directors to five; providing strengthened governance and succession for
possible future rotation of Board members.

Stuart Gall is CEO of Intelligent Ultrasound, an AIM-listed medical imaging
company providing one of the world's leading 'classroom to clinic' ultrasound
technologies. Previous appointments include joint founder and executive
director of Fusion IP plc, an AIM listed university IP commercialisation
company, before its purchase by IP Group plc for £103 million in 2014. Stuart
has over 30 years' experience in both small company start-ups and public
companies and previously worked at British Airways plc, The Promotions
Partnership Limited, Anvil Limited and Toad plc (now Journeo plc).

Nick Rodgers is currently Chair of SEHTA, one of the largest health technology
membership and networking organisations in the UK supporting businesses in the
health technology sector. Until 2023 Nick was Chair of Destiny Pharma plc, a
developer of novel anti-infective products and chair of ZPN Energy Limited, a
developer of battery storage technologies and systems for the electric vehicle
market. Previously, until 2016, Nick was chairman of Oxford BioMedica plc, a
pioneer of gene and cell therapy and a leader in lentiviral vector research,
development and bioprocessing.

Dr Steven Powell, Chairman of Cambridge Cognition, commented:

"On behalf of the Board, I am delighted to welcome Stuart and Nick to
Cambridge Cognition. Their broad expertise and deep industry experience in the
healthcare and technology sectors will be extremely valuable in the next stage
of Cambridge Cognition's development now that we have integrated the two
acquisitions made in 2022/23, which strengthen the Company's product offering
and cement its leading market position.  We look forward to benefitting from
their insights as the Board continues to lead Cambridge Cognition to
profitability and accelerate and execute the Company's growth plans."

 

Further information:

The following details in relation to the appointments of Stuart Gall and Nick
Rodgers as directors of the Company are disclosed in accordance with AIM Rule
17 and Schedule 2(g) of the AIM Rules for companies:

Stuart Arthur Gall (aged 61 years) holds or has held the following
directorships or partnerships in the last five years:

 Current                                   Past 5 years
 Intelligent Ultrasound Limited            DEMASQ Limited
 Intelligent Ultrasound Group plc          I2LResearch Ltd
 Medaphor International Limited
 Medaphor Limited
 Inventive Medical Limited
 IML Finance Ltd
 Intelligent Ultrasound North America Inc

 

Stuart was also a director of Abcellute Limited and Abcellute Tissue Bank
Limited at the time that both companies entered into a creditors liquidation
on 10 October 2012. Abcellute Limited was subsequently dissolved on 17
September 2016 and Abcellute Tissue Bank Limited was dissolved on 10 March
2016.

Philip Nicholas 'Nick' Rodgers (aged 65 years) holds or has held the following
directorships or partnerships in the last five years:

 Current                                                       Past 5 years
 Science and Engineering Health Technologies Alliance Limited  Alcuris Ltd
 SEHTA Enterprises Limited                                     Destiny Pharma plc
 Nick Rodgers Financial Limited                                Interactive Me Ltd
 Productiv Limited                                             Powerme Leasing Ltd
                                                               Productiv Property Limited
                                                               Productiv Technology Limited
                                                               The Proving Factory Limited
                                                               Zapme Limited
                                                               ZPN Energy Limited

 

Productiv Limited, a company which Nick Rodgers is a director of, entered into
a creditors voluntary liquidation on 21 November 2022. The Company is
currently still in liquidation.

Save as disclosed above, there is no further information to be disclosed in
relation to appointments of Stuart Gall or Nick Rodgers pursuant to AIM Rule
17 or Schedule Two, paragraph (g) of the AIM Rules for Companies.

The information contained within this announcement is deemed by the Company to
constitute inside information stipulated under the Market Abuse Regulation
(EU) No. 596/2014 as it forms part of UK domestic law by virtue of the
European Union (Withdrawal) Act 2018.  Upon the publication of this
announcement via the Regulatory Information Service, this inside information
is now considered to be in the public domain.

 

Enquiries

 Cambridge Cognition Holdings plc
 Matthew Stork, Chief Executive Officer            Tel: 01223 810 700

 Stephen Symonds, Chief Financial Officer          press@camcog.com (mailto:press@camcog.com)

 Panmure Gordon (UK) Ltd (NOMAD and Joint Broker)  Tel: 020 78862500

 Freddy Crossley / Emma Earl / Mark Rodgers        (Corporate Advisory)

 Rupert Dearden                                    (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)            Tel: 020 3903 7715

 David Poutney / James Serjeant                    (Corporate Broking)

 Hudson Sandler (Financial PR and IR)              Tel: 020 7796 4133

 Dan de Belder / Hattie Dreyfus                    cog@hudsonsandler.com (mailto:cog@hudsonsandler.com)

 

 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com
(http://www.cambridgecognition.com)

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAGZGZMNLRGDZM